Videos

Julia White, MD, professor of Radiation Oncology, Ohio State University Comprehensive Cancer Center, discusses the relationship between multigene assays and radiation therapy in patients with breast cancer.

Kathleen L. O'Connor, MD, professor, associate director of Cancer Education, Department of Molecular and Cellular Biochemistry, University of Kentucky Markey Cancer Center, discusses the ongoing research in the field of breast cancer.

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3k pathway in patients with metastatic breast cancer.

Approximately 46% of patients with breast cancer at high risk for recurrence but low genomic risk with the 70-gene breast cancer recurrence assay (MammaPrint) might not require adjuvant chemotherapy.

The European Medicines Agency has validated the marketing authorization application for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.

Clifford A. Hudis, MD, CEO, ASCO, discusses how oncologists should be helping patients with breast cancer overcome obesity.

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor-Sammons Cancer Center, discusses what’s on the horizon in triple-negative breast cancer (TNBC). Checkpoint inhibitors, such as an anti-PD-1 agents, show a lot of promise in TNBC, said O’Shaughnessy. There are several studies investigating the use of checkpoint inhibitors with platinum agents and the preliminary data looks very good, she said.

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses steps needed to take in the field of HER2-positive breast cancer from a research perspective.

A 2-mm margin should be the standard for patients with ductal carcinoma in situ undergoing breast conserving surgery with whole breast irradiation.

The phase III MONARCH 2 study assessing abemaciclib in HR-positive, HER2-negative advanced breast cancer will continue after the CDK4/6 inhibitor did not meet the efficacy criteria at an interim analysis required to stop the trial early.

J. Michael Dixon, MD, professor of Surgery, consultant surgeon, and clinical director of the Breakthrough Breast Cancer Research Unit at the University of Edinburgh in Scotland, discusses the prevalence of and risk factors for breast cancer in males.

Carlos L. Arteaga, MD, associate director for Clinical Research, director, Center for Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center, discusses some of the ongoing trials exploring treatments for patients with metastatic breast cancer.

Constance D. Lehman, MD, PhD, professor of radiology and chief of Breast Imaging in the Department of Radiology at Massachusetts General Hospital, discusses how 3D mammography has been an efficient and beneficial screening tool in the field of breast cancer.

​Harold J. Burstein, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute discusses the results of MONARCH1, which looked at abemaciclib as monotherapy in patients with ER-positive breast cancer, after chemotherapy for advanced disease.

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses de-escalating surgery in the treatment of patients with breast cancer.

The FDA has granted a breakthrough therapy designation to the CDK4/6 inhibitor ribociclib in combination with letrozole for its potential as a frontline therapy for patients with HR-positive, HER2-negative advanced breast cancer.

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the unmet need for patients with HER2-positive breast cancer.

Jennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.

Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer, according to a joint analysis of the Anthracyclines in Early Breast Cancer (ABC) trials.

Cynthia Ma, MD, PhD, associate professor of Medicine, Washington University School of Medicine, discusses the METRIC trial in triple-negative breast cancer.

Cynthia Ma, MD, provides insight on the potential of glembatumumab vedotin (CDX-011) and immunotherapies on the horizon in the field of triple-negative breast cancer.

Collective findings from clinical trials show that, for women with early-stage breast cancer who have a low 21-gene recurrence score, adding chemotherapy to standard hormonal therapy does not show a difference in survival.

In terms of neoadjuvant therapies for patients with HER2-positive breast cancer, dual anti–HER2-directed agents seem to have the most benefit.

Joseph Sparano, MD, associate chairman, Clinical Research, Department of Oncology, Montefiore Medical Center, associate director, Clinical Research, Albert Einstein Cancer Center, discusses the ways in which the role of endocrine therapy has evolved over the years as a treatment for patients with breast cancer.